MedTrace Logo

Clinical Trial to Assess the Preventive Effects of Cetylpyridinium Chloride on Sarcopenia

NCT02575235 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-10-08

No results posted yet for this study

Summary

This study is to assess the impact on the prevention of sarcopenia after taking cetylpyridinium chloride targeting the patients of pre-sarcopenia or sarcopenia over the age of 60

Conditions

Interventions

DRUG

Cetylpyridinium Chloride (CPC)

Two study groups take CPC of 1.5mg and 4.5mg daily for four weeks.

DRUG

placebo

Control group takes the placebo for the same period.

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-01
Primary Completion
2016-07-01
Completion
2016-07-01

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02575235 on ClinicalTrials.gov